Cipla Ltd.

United States Food and Drug Administration (USFDA) has completed a routine cGMP inspection for both Formulations and APIs at Cipla’s manufacturing facility in Patalganga from November 4, 2019 to November 13, 2019.

The inspection ended with 4 observations, none of which were repeat or related to data integrity. The Company is committed to addressing these observations and will submit its response to the agency within the stipulated time.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.